MX2010001371A - Carboxamidas opioides cuaternarias. - Google Patents

Carboxamidas opioides cuaternarias.

Info

Publication number
MX2010001371A
MX2010001371A MX2010001371A MX2010001371A MX2010001371A MX 2010001371 A MX2010001371 A MX 2010001371A MX 2010001371 A MX2010001371 A MX 2010001371A MX 2010001371 A MX2010001371 A MX 2010001371A MX 2010001371 A MX2010001371 A MX 2010001371A
Authority
MX
Mexico
Prior art keywords
carboxamides
opioid
quaternary
quaternary opioid
compounds
Prior art date
Application number
MX2010001371A
Other languages
English (en)
Spanish (es)
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of MX2010001371A publication Critical patent/MX2010001371A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
MX2010001371A 2007-08-09 2008-08-08 Carboxamidas opioides cuaternarias. MX2010001371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95496007P 2007-08-09 2007-08-09
PCT/US2008/072632 WO2009023567A1 (en) 2007-08-09 2008-08-08 Quaternary opioid carboxamides

Publications (1)

Publication Number Publication Date
MX2010001371A true MX2010001371A (es) 2010-03-10

Family

ID=39941437

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001371A MX2010001371A (es) 2007-08-09 2008-08-08 Carboxamidas opioides cuaternarias.

Country Status (14)

Country Link
US (4) US8263807B2 (enExample)
EP (1) EP2190819B1 (enExample)
JP (1) JP5581211B2 (enExample)
KR (1) KR101519682B1 (enExample)
CN (1) CN101827819B (enExample)
AU (1) AU2008286979B2 (enExample)
BR (1) BRPI0815020A2 (enExample)
CA (1) CA2694497C (enExample)
EA (1) EA020658B1 (enExample)
ES (1) ES2586245T3 (enExample)
IL (1) IL203459A (enExample)
MX (1) MX2010001371A (enExample)
NO (1) NO341089B1 (enExample)
WO (1) WO2009023567A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008331235C1 (en) * 2007-11-30 2013-01-17 Purdue Pharma L.P. Benzomorphan Compounds
EP2408303A4 (en) * 2009-03-19 2012-07-25 Alkermes Inc MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
PT2506712T (pt) * 2009-12-04 2019-05-31 Alkermes Pharma Ireland Ltd Derivados de morfinano para o tratamento da overdose por fármaco
ES2582306T3 (es) * 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
JP5728084B2 (ja) * 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
EP2407469A1 (en) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
AU2012217903A1 (en) * 2011-02-14 2013-08-15 Alkermes, Inc. Peripherially acting mu opioid antagonists
AU2012247127B2 (en) * 2011-03-03 2016-01-28 Cadila Healthcare Limited Novel salts of DPP-IV inhibitor
US9029543B2 (en) * 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
ES2638329T3 (es) * 2011-06-29 2017-10-19 Alkermes, Inc. Compuestos opioides de acción periférica
WO2013084060A1 (en) * 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3153171B1 (en) 2011-12-15 2018-09-19 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
WO2016138103A1 (en) * 2015-02-25 2016-09-01 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN115521317B (zh) * 2021-02-02 2025-07-25 山东新时代药业有限公司 一种制备纳呋拉啡中间体的方法
WO2025104754A1 (en) * 2023-11-17 2025-05-22 Msn Laboratories Private Limited, R&D Center A process for the preparation of samidorphan and its intermediates
CN118598813B (zh) * 2024-08-08 2024-10-29 山东齐都药业有限公司 L-苹果酸萨米多芬及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874217A (en) * 1958-10-30 1961-08-02 Albert Boehringer Normorphine derivatives
DE2254298A1 (de) * 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
GB1511319A (en) * 1974-09-20 1978-05-17 Sterling Drug Inc 2,6-methane-3-benzazocine derivatives and their preparation
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
CA1315689C (en) * 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
KR19990077125A (ko) 1996-01-10 1999-10-25 파올로 비지, 엔리꼬 카쭐라니 헤테로고리-축합 모르핀 유도체 (ⅱ)
ES2121553B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
CA2380524A1 (en) * 1999-08-25 2001-03-01 Barrett R. Cooper Compositions and methods for treating opiate intolerance
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
ATE292625T1 (de) * 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
KR20050074462A (ko) * 2002-09-25 2005-07-18 유로-셀티큐 에스.에이. Ｎ―치환 하이드로모르폰 및 그 용도
US7285665B2 (en) * 2002-11-08 2007-10-23 Mallinckrodt Inc. Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
RU2480455C2 (ru) 2004-11-05 2013-04-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents

Also Published As

Publication number Publication date
IL203459A (en) 2016-02-29
CA2694497C (en) 2016-07-12
HK1141295A1 (zh) 2010-11-05
AU2008286979B2 (en) 2013-03-28
EP2190819B1 (en) 2016-05-25
US20120302594A1 (en) 2012-11-29
KR20100053627A (ko) 2010-05-20
EA201070237A1 (ru) 2010-10-29
CN101827819B (zh) 2013-06-12
BRPI0815020A2 (pt) 2015-03-10
AU2008286979A1 (en) 2009-02-19
WO2009023567A1 (en) 2009-02-19
US20090197905A1 (en) 2009-08-06
EP2190819A1 (en) 2010-06-02
JP2010535814A (ja) 2010-11-25
KR101519682B1 (ko) 2015-05-19
US8263807B2 (en) 2012-09-11
NO341089B1 (no) 2017-08-21
NO20100289L (no) 2010-03-02
ES2586245T3 (es) 2016-10-13
US8563572B2 (en) 2013-10-22
CN101827819A (zh) 2010-09-08
US20140107143A1 (en) 2014-04-17
JP5581211B2 (ja) 2014-08-27
EA020658B1 (ru) 2014-12-30
US20170095469A1 (en) 2017-04-06
CA2694497A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
MX2010001371A (es) Carboxamidas opioides cuaternarias.
PL2059243T3 (pl) Buprenorfina w opłatku do farmakologicznego leczenia substytucyjnego
GB0609492D0 (en) Therapeutic agents
MY145795A (en) Pyrazoline compounds
PL2086642T3 (pl) DNaza do leczenia męskiej subpłodności
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
IL201235A0 (en) Therapeutic agents
ZA200900004B (en) Therapeutic compounds
GB0603041D0 (en) Therapeutic compounds
GB0723747D0 (en) Therapeutic agents
GB0616214D0 (en) Therapeutic Agents
GB0724340D0 (en) Novel Therapeutic Agents
GB0606663D0 (en) Therapeutic compounds
EP1968603A4 (en) THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
GB0611152D0 (en) Therapeutic agents
ZA200901094B (en) Methods and tools for the therapy of neurodegenerative pathologies
GB0620059D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
PL1727545T3 (pl) Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
GB0625345D0 (en) Therapeutic compounds
GB0603455D0 (en) Therapeutic compounds
ZA200807678B (en) Meridamycin analogues for the treatment of neurodegenerative disorders
GB0723748D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
FG Grant or registration